Meileen Acosta.

Janice K. Louie, M .D., M.P.H., Meileen Acosta, M.P.H., Denise J. Jamieson, M.D., M.P.H., and Margaret A. Honein, Ph.D., M.P.H. For the California Pandemic Working Group: Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California As in previous influenza epidemics and pandemics, pregnant women with 2009 pandemic influenza A appear to have an increased threat of severe disease.1-7 From April 23 to August 11, 2009, a total of 10 percent of the 1088 patients who were hospitalized with or died from 2009 H1N1 influenza, while reported to the California Department of Public Wellness , were pregnant.8 A recent statement from the first month of the outbreak noted that the price of hospitalization among women that are pregnant was approximately four times the rate in the general population.5 This record describes the clinical course of the characteristics and disease of hospitalized pregnant, postpartum, and non-pregnant reproductive-age women with 2009 H1N1 influenza for whom data had been reported to the CDPH in the first 4 months of the pandemic.

A total of 13 patients were withdrawn from the analysis during the 2-month period where the dosage of ramipril was risen to the maximum dosage. The good known reasons for withdrawal included demand by the patient, loss to follow-up, or non-compliance , hyperkalemia , and severe deterioration of the glomerular filtration price . During the course of the scholarly study, 92 patients were withdrawn before achieving the primary end stage; the reasons for withdrawal included transition to adult units , patient’s demand , nonadherence with acquiring the study medication , hyperkalemia , hypotension , and other adverse occasions . The rate of withdrawal for factors other than achieving the primary end point was 5.5 percent each year, as compared with rates of 10 to 21 percent each year which have been reported in trials of renoprotection in adults.4,5,17,18 The types and incidences of adverse events didn’t differ significantly between the two groups .